Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
ARR-002 · 1 trial · 5 indications
AEs that occur or worsen on or after the first dose of study treatment
Incidence of dose-limiting toxicities (DLTs) and serious adverse events (SAEs)
| Arm | Type | Description |
|---|---|---|
| ARR-002 | EXPERIMENTAL | - |
| Name | Type | Description |
|---|---|---|
| ARR-002 | DRUG | ARR-002 will be administrated as specified in the protocol. |
Inclusion Criteria: * Patients with histologically and cytologically confirmed advanced or metastatic ovarian, primary peritoneal, or fallopian tube cancer, and platinum resistant who have failed or intolerant to standard therapy, or without alternative standard therapy. * Patients must have at lea...
Top 20 of 59 competitors
ARR-002 is an investigational small molecule being developed for the treatment of ovarian cancer, including platinum-resistant ovarian cancer and metastatic ovarian cancer. It is also being studied in endometrial cancer. The drug is currently in Phase 1 clinical development and has not been approved by the FDA.
ARR-002 targets MUC16 and NaPi2b, which are antigens associated with certain cancers. By targeting these antigens, the drug is designed to interfere with cancer cell activity. This mechanism is being evaluated in a Phase 1 clinical trial for ovarian and endometrial cancers.
ARR-002 is being developed by ArriVent BioPharma, Inc., a biopharmaceutical company traded on the NASDAQ under the ticker symbol AVBP. The company is conducting a Phase 1 clinical trial to assess the safety, tolerability, pharmacokinetics, immunogenicity, and antitumor activity of ARR-002 in patients with advanced or metastatic ovarian or endometrial cancer.
ARR-002 is in Phase 1 clinical development. It is an investigational drug and has not been approved by the FDA. The ongoing Phase 1 trial is recruiting patients in the United States and is designed to evaluate the drug's safety, tolerability, and preliminary antitumor activity in advanced or metastatic ovarian and endometrial cancers.
ARR-002 is being studied in a Phase 1 clinical trial with the identifier NCT07755436. This trial is recruiting female patients aged 18 years and older with advanced or metastatic ovarian or endometrial cancer, including platinum-resistant ovarian cancer. The study is uncontrolled, not randomized, and not double-blinded, with a planned enrollment of 180 participants.
No alternative names for ARR-002 have been reported. The drug is identified solely as ARR-002 in clinical trial records and by its developer, ArriVent BioPharma, Inc. It is a distinct investigational small molecule being evaluated for the treatment of ovarian and endometrial cancers.